InDex Pharmaceuticals Holding AB (publ) EBIT

InDex Pharmaceuticals Holding AB (publ) posts a EBIT of $-56M as of March 2024. That compares with $-130M in the prior-year period — up 56.2% year over year. That is below the Healthcare sector average of $99B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, InDex Pharmaceuticals Holding AB (publ)'s EBIT was $-130M. The latest reading is $-56M — a 56.2% year-over-year increase (period ending March 2024). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $99B is typical. InDex Pharmaceuticals Holding AB (publ)'s $-56M is lower that level. That is roughly 100.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of InDex Pharmaceuticals Holding AB (publ)'s financial statement story. At $-56M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for INDEX.ST's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $99B), and (3) consistency with growth and profitability. This page covers the first two; InDex Pharmaceuticals Holding AB (publ)'s other metric pages and overview cover the third.